Agios Financial Statements From 2010 to 2024
| 8AP Stock | EUR 52.50 1.50 2.94% |
Check Agios Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Agios Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Agios financial statements analysis is a perfect complement when working with Agios Pharmaceuticals Valuation or Volatility modules.
Agios |
Agios Pharmaceuticals Company Shares Outstanding Analysis
Agios Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Agios Pharmaceuticals Shares Outstanding | 54.94 M |
Most of Agios Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Agios Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Agios Pharmaceuticals has 54.94 M of shares currently outstending. This is 69.57% lower than that of the Healthcare sector and 48.58% lower than that of the Biotechnology industry. The shares outstanding for all Germany stocks is 90.39% higher than that of the company.
Agios Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Agios Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Agios Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Agios Pharmaceuticals competition to find correlations between indicators driving Agios Pharmaceuticals's intrinsic value. More Info.Agios Pharmaceuticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Agios Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Agios Pharmaceuticals Financial Statements
Agios Pharmaceuticals stakeholders use historical fundamental indicators, such as Agios Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Agios Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Agios Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Agios Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Agios Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts. AGIOS PHARMACEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 482 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Agios Stock
Agios Pharmaceuticals financial ratios help investors to determine whether Agios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Agios with respect to the benefits of owning Agios Pharmaceuticals security.